Alzheimer’s: biomarkers redefine disease
Biological markers (biomarkers) for Alzheimer’s disease (AD) assess risk as well as the presence and progression of the disease. AD biomarkers are derived from cerebrospinal fluid (CSF) and plasma. Some biomarkers have been evaluated as part of regulatory guideline documents, often in Phase II drug development trials establishing safety and tolerance. Large-scale multi-centre trials are […]
